• 1
    Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 71323.DOI: 10.1046/j.1523-1755.1999.00299.x
  • 2
    Scheuer PJ, Williams R, Muir AR. Hepatic pathology in relatives of patients with hemachromotosis. J Pathol Bacteriol 1962; 84: 5364.
  • 3
    First MR. Expanding the donor pool. Sem Nephrol 1997; 17: 373.
  • 4
    United Network for Organ Sharing. UNOS Scientific Registry data, 10282002.
  • 5
    Xue JL, Ma JZ, Louis TA et al. Forecast of the number of patients with end stage renal disease in the united states to the year 2010. J Am Soc Nephr 2001; 12: 27.DOI: 10.1159/000047677
  • 6
    Shaheen FA, Sheikh IA, Awad A et al. Use of marginal donors in kidney transplantation. Transplant Proc 2002; 34: 24542455.
  • 7
    Randhawa P. Role of donor kidney biopsies in renal transplantation. Transplantation 2001; 71: 13611365.
  • 8
    Rosengard BR, Feng S, Alfrey EJ et al. Report of the Crystal City meeting to maximize the use of organ recovered from the cadaver donor. Am J Transplant 2002; 2: 110.DOI: 10.1034/j.1600-6143.2002.020101.x
  • 9
    Fahr T. Pathologische Anatomie des Morbus Brightii. In: Henke F, Lubarsch O (eds). Handbuch der Speziellen Pathologischen Anatomie und Histologie. Berlin : Springer, 1925; 6: 156. [PMID 7155980]
  • 10
    Althoff H. Massive renal hemosiderosis in Marchiafava anemia and the possibility of an in-vitro desferrization through desferriofamine B. Gegenbaurs Morphologisches Jahrbuch 1967; 111: 292300. [In German ]
  • 11
    Koliakos G, Papachristou F, Koussi A, Perifanis V, Tsatra I, Souliou E. Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia. Clin Lab Haematol 2003; 25: 105109.
  • 12
    Pardo-Mindan FJ, Diez J, Esparza N, Robledo C. Renal siderosis in patients with heart-valve prostheses: clinical implications. Nephrol Dial Transplant 1990; 5: 847850.
  • 13
    Toszegi A, Boti Z, Kovacs G. Renal siderosis in cardiac intravassal hemolysis. Morphol Igazsagugyi Orv Sz 1981; 21: 224231.
  • 14
    Zager RA, Foerder CA. Effects of inorganic iron and myoglobin on in-vitro proximal tubular lipid peroxidation and cytotoxicity. J Clin Invest 1992; 89: 989995.
  • 15
    Nankivell BJ, Boadle RA, Harris DC. Iron accumulation in human chronic renal disease. Am J Kidney Dis 1992; 20: 580584.
  • 16
    Nath KA, Balla G, Vercelloti GM et al. Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. J Clin Invest 1992; 90: 267270.
  • 17
    Paller MS, Hedlund BE. Role of iron in postischemic renal injury in the rat. Kidney Int 1988; 34: 474480.
  • 18
    Salahudeen A, Nawaz M, Poovala V et al. Cold storage induces time-dependent F2-isoprostane formation in renal tubular cells and rat kidneys. Kidney Int 1999; 55: 1759.DOI: 10.1046/j.1523-1755.1999.00390.x
  • 19
    Huang H, He Z, Roberts IILJ, Salahudeen AK. Deferoxamine reduces cold-ischemic renal injury in a syngeneic kidney transplant model. Am J Transplant 2003; 3: 1531.DOI: 10.1046/j.1600-6135.2003.00264.x